Related Experiment Video
Updated: May 1, 2026
13:04
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
23.7K
Rapid diagnostic HCV antibody assays
Bryce D Smith1, Amy Jewett, Jan Drobeniuc
1Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA, USA. bli1@cdc.gov
Antiviral Therapy
|January 17, 2013
Summary
Rapid hepatitis C virus (HCV) tests can help identify infected individuals unaware of their status. Performance varied among pre-market assays, highlighting the need for further evaluation and development of advanced HCV detection methods.
Area of Science:
- Hepatology
- Infectious Diseases
- Diagnostic Assays
Background:
- Hepatitis C virus (HCV) affects approximately 4.1 million Americans.
- A significant percentage (45-85%) of chronically infected individuals remain unaware of their infection.
- Early identification is crucial for effective management and prevention of HCV transmission.
Purpose of the Study:
- To evaluate the performance characteristics of pre-market rapid anti-HCV assays.
- To assess the utility of these rapid tests in identifying individuals with unknown HCV status.
Main Methods:
- Performance of three rapid anti-HCV assays (Chembio, MedMira, OraSure) was evaluated.
- Key performance metrics assessed included sensitivity and specificity.
Main Results:
- Sensitivity of the evaluated assays ranged from 78.9% to 99.3%.
- Specificity ranged from 80% to 100%.
- Performance characteristics varied across the different rapid anti-HCV tests.
Conclusions:
- Rapid anti-HCV assays show potential for identifying unaware individuals.
- Further research is needed, including evaluation in co-infected populations (HCV/HIV).
- Development of rapid HCV-antigen and nucleic acid tests is recommended for improved diagnostics.
